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Research article
Ερευνητικό άρθρο
ABSTRACT. The present study was carried out to determine the effects of sub-chronic thinner addiction on the ox-
idant-antioxidant balance and oxidative stress on certain tissues and the possible protective effect of safranal against 
thinner toxication in rats. Adult male Wistar albino rats were randomly divided into four groups of 10 animals each 
as follows: control (C), safranal (S), thinner (T) and thinner+safranal (T+S). The control group received 1cc saline by 
gastric gavage. Safranal was administered to S and T+S groups by using gastric gavage at a dose of 100 mg/kg/day and 
volume of 0.1 mL/kg/day. Thinner inhalation was applied to T and T+S groups in a container with NaOH tablets twice 
a day. Levels of malondialdehyde (MDA), reduced glutathione (GSH), nitric oxide (NO
x
) metabolites, total antioxidant 
capacity (TAS) and total oxidant capacity (TOS) were determined in liver, lung, brain, kidney and testis tissues of the 
rats. In the T+S group, it was observed that the MDA levels significantly decreased in all tissues, except the kidney, in 
comparison to the thinner inhalation group (p = 0.000). When the NOx levels of the T+S group were compared with 
the levels of the T group, it was concluded that there existed a statistically significant decrease in the NOx levels in all 
tissues (p = 0.000).
In T+S group, it was observed that safranal either eliminated or mitigated oxidative stress that developed in tissues 
through decreasing MDA and TOS levels and increasing GSH and TAS levels and caused significant decreases in NO
X
 
levels in all tissues. As a result, it was determined that safranal, although not uniform for all tissue types, had a protec-
tive potential against the damaging effects of oxidative stress caused by sub-chronic thinner inhalation. 
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INTRODUCTION
Thinner is an organic solvent which is common-ly used for industrial applications and currently 
has an increasing improper use as a pleasure inducing 
and narcotic substance. Thinner is a mixture of tol-
uene, benzene, acetone, methanol, hexane and other 
substances (Nedzvetskii et al., 2012). It was indicated 
that the thinner used in Turkey was composed of 63% 
of toluene, 13% of acetone, 10% of isobutyl acetate, 
7.5% of isobutane and 6.5% of butylene glycol and its 
harmful effects were mostly associated with toluene, 
where the remaining substances activated these harm-
ful effects (Cobanoglu et al., 2007). 
Reactive oxygen (ROS) and nitrogen (RNS) de-
rivatives occur in the organism due to exposure to en-
vironmental and chemical agents and the interaction 
of such derivatives with macromolecules leads to ox-
idative stress (Mattia et al., 2003). Similar to various 
internal and external toxic agents, the toxic effects of 
thinner also emerge through free radicals (Mattia et 
al. 1991, Martínez-Alfaro et al., 2011). 
Long-term use of volatile organic solvents has 
been shown to cause permanent damage to the lung 
and liver (Marjot and McLeod, 1989; Al-Alousi, 
1989). Mattia et al. (1991; 1993a,b) reported in vivo 
and in vitro studies that ROS formation is accelerated 
and lipid peroxidation is increased in brain, liver, kid-
ney and lung tissues with the effect of intraperitoneal 
administration of toluene. Al-Alousi (1989) empha-
sized that pulmonary edema is the cause of death due 
to volatile substances. When the results of many stud-
ies are considered, it has been observed that there are 
many damages as a result of using thinner in industri-
al area and for narcotic use. Studies show that MDA 
levels increase and GSH levels decrease due to degra-
dation of lipid peroxidation due to oxidative stress of 
organic solvents (Ulakoglu et al. 1998b, Dillioglugil 
et al. 2005, El-Nabi Kamel and Shehata 2008).
In recent years, research in phytotherapy focused 
on the effects of the components in plant extracts on 
various diseases, rather than the effect of plant ex-
tracts. Safranal is one of the components of saffron 
extract. Saffron is an herb with antioxidant effects, 
included in medical literature and is acknowledged 
to have an increasing significance due to its thera-
peutic effects (Moghaddasi, 2010; Assimopoulou et 
al., 2015).The radical scavenging activity of safranal 
results with antidiabetic, antioxidant, anticancer and 
hypotensive properties, thus various studies conclud-
ed that safranal could be used in industries such as 
food, pharmaceuticals and cosmetics (Assimopou-
lou et al., 2005, Imenshahidi et al., 2010, Hazman ve 
Bozkurt, 2015). Karafakioglu et al. (2017) reported 
that safranal (200 mg / kg) treatment may have a pro-
tective effect against cisplatin-induced nephrotoxic-
ity and oxidative stress in rats. Alayunt et al.(2019) 
observed that particularly high-dose (100 mg/kg) ad-
ministration of safranal to rats promoted the antioxi-
dant system and be inflammatory against TNF-α and 
IL-6 cytokines on damage induced by CCl4.
The main aim of our study is to investigate to what 
extent thinner, which is a mixture of organic solvent, 
affects brain, lung, liver, kidney, testis via respiratory 
system and to investigate the effect of safranal on this 
condition. The results of the study may contribute to 
the development of new approaches both in the pro-
tection of worker health on an industrial scale and in 
the treatment of addicts using volatile substances.
MATERIALS AND METHODS
Chemicals
Safranal (Cat no:Sigma-W338907), Total oxidant 
(TOS) and antioxidant status (TAS) commercial kits 
(Rell Assay:RL0024, RL0017) and the other chemical 
used in the study were purchased from Sigma -Al-
drich (Sigma Aldrich Chemical Co. 
St. Louis, Missouri, ABD).
Animals
In the present study , 40 Wistar albino male rats 
(weighing ~250-300 g) were used. The animals were 
housed under standard conditions of temperature 
(23 ± 2°C), humidity, and dark-light cycle (lights on 
from 6:00 am to 6:00 pm).. Throughout the study, 
the rats were maintained on standard rat feed and tap 
water ad libitum. They were fed twice daily at 0900 
and 1900. Before starting the thinner experiments, 
rats were subjected to preexperiments in order to pre-
vent possible toxication severity complications.  All 
the animals were carefully monitored and maintained 
in accordance with the ethical recommendation of 
the University of Afyon Kocatepe Animal Ethics 
Committee The permission was gained on 7 May 
2015 with the number 49533702/46.
Experimental procedure
A total of 40 rats were included in the study. They 
were divided into 4 groups as follows: Control Group 
(C) (n=10), Sub-chronic Thinner Inhalation Group 
(T) (n=10), Sub-chronic Thinner Inhalation + Sa-
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franal Group (T+S) (n=10) and Safranal Group (S) 
(n=10). Control group (C); comprised 10 healthy 
rats. The rats in the control group were administered 
1 cc of physiological saline daily by gastric gavage 
for 8 weeks. Rats were fed with standard rat feed for 
8 weeks and their weights were recorded regularly 
during the experiments. Sub-chronic Thinner Inha-
lation Group (T); rats were placed in a specially de-
signed cage size 100x60x40 cm with air ventilation 
that allowed inhalation of controlled amounts of thin-
ner (5ml). This application was repeated twice a day 
for 8 weeks and was terminated when 50% of the rats 
lost their reflexes to stand (About 5-6 min) (Konuk 
et al., 2012). Sub-chronic Thinner Inhalation+Sa-
franal Group (T+S); treated as T group and addition-
ally a dose of 100 mg/kg of safranal dissolved in 1 
cc of physiological saline solution was administered 
via gastric gavage for 8 weeks. Commercial safran-
al (Sigma-w338907) was used in the study. Safranal 
Group (S); a dose of 100 mg/kg of safranal dissolved 
in 1 cc of physiological saline solution was adminis-
tered via gastric gavage for 8 weeks. The dose of sa-
franal used in this study was based on previous stud-
ies (Hosseinzadeh et al., 2013; Hazman ve Bozkurt, 
2015; Hazman and Ovalı, 2015).
Sample preparation
At the end of the experimental period, the rats were 
anesthetized and sacrificed by cervical dislocation. 
Rats were anesthetized with 10 mg/kg-im xylazine 
and 50 mg/kg-im ketamine injection. All rats were 
sacrificed on the 56th day (8 weeks) of the experiment 
and tissue samples (brain, lung, liver, kidney, testis) 
were collected for examination of clinical biochemi-
cal analysis. Tissue samples (0.5 g) were placed in ho-
mogenizer and were added 5 mL of phosphate buffer 
solution (PBS) (pH: 7.4) and were homogenized by 
means of the homogenizer and the sonicator. The ho-
mogenates were centrifuged at 15000xrpm and +4˚C 
for 10 minutes, and the supernatants were stored at 
-80 °C in deep freeze pending analysis. 
Measurement of parameters
In the obtained supernatants, the Malondialdehyde 
(MDA) levels were determined according to Ohka-
wa et al. (1979), the reduced glutathione (GSH) an-
alyzes were conducted based on Beutler (1963) and 
the amounts of Nitric oxide (NOx) were determined 
via the “Vanadium chloride (III) - Gries Reaction” 
method of Miranda et al. (2001). Total oxidant (TOS) 
and antioxidant status (TAS) measurements were 
performed via Eliza Reader (Biotek, ELx800) using 
commercial kits based on the method developed by 
Erel (2004, 2005). The amount of toluene in the blood 
was measured and the level of inhalation in T and T 
+ S groups were determined. The toluene levels in 
the rats’ blood were determined using the GS-MS in 
Acıbadem Labmed Central Laboratory (Istanbul, Tur-
key).
Statistical analysis
ANCOVA method was used for statistical analysis 
and the difference between the groups was tested us-
ing the Bonferroni test. The live weight averages of 
the groups at the zeroth and eighth week were chosen 
as the covariate. Data were analyzed using the SPSS® 
24 package program. The results were expressed as 
“mean±standard error” (X±SE) and p <0.05 was con-
sidered as the significance value.
RESULTS 
Blood toluene levels
Blood toluene levels of rats that inhaled sub-chron-
ic thinner are presented in Table 1. No statistically 
significant difference was determined for inhaled tol-
uene levels in T and T+S groups. 
MDA levels measured in tissue samples
The changes in MDA, which is an indicator of 
from lipid peroxidation, in the liver, lung, kidney, 
brain and testis tissue samples retrieved from the four 
experiment groups constituted in the present study, 
are presented in Table 2. Comparing the MDA levels 
of the T group with that of the control group levels it 
could be observed that a significant increase of MDA 
levels were determined in liver, lung, testis and kid-
ney tissues (p=0.000).
GSH levels measured in tissue samples
The GSH levels in groups are presented in Table 3. 
It was observed that GSH levels in liver, kidney brain, 
and testis tissues was a significant decreased between 
T group and that of the control groups (Respectively 
p=0.013; p=0.000; p= 0.015; p= 0.007)
TAS and TOS levels measured in tissue samples
Changes of TAS and TOS levels in all tissues in 
groups are presented in Table 4 and Table 5, respec-
tively. Comparing the TAS levels of the T group with 
that of the control group levels it was determined that 
TAS levels only significantly decreased in liver and 
kidney tissues (p=0.000). It was identified that liv-
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er and brain TOS levels only significantly increased 
between the T group and that of the control group 
(p=0.000; p=0.001). It was observed that the liver 
and kidney tissues TAS levels significantly increased 
between T+S group and that the T group (p =0.000). 
It was concluded that liver tissue TOS levels signifi-
cantly decreased between the T+S group and the T 
group (p =0.000).
NOx levels measured in tissue samples
The changes in the NO
x
 levels obtained from all 
tissues of the experiment groups are presented in Ta-
ble 6. It was observed that the NO
x
 level significant-
ly increased only in the brain tissue between T group 
and the control group (p=0.000). When the NO
x
 levels 
of the T+S group were compared with the levels of 
the T group, it was concluded that there existed a sta-
tistically significant decrease in the NO
x
 levels in all 
tissues (p =0.000).
Table 1. Blood toluene levels of rats in T and T+S groups
Groups
C
x±SE
S
x±SE
T
x±SE
T+S
x±SE p
Toluene (ng/ml) - - 1,525±0,071 1,481±0,071 0,730
C: Control Group; T : Sub-chronic Thinner Inhalation Group; T+S: Sub-chronic Thinner Inhalation + Safranal Group; 
S: Safranal Group; X ± SE: mean ± standard error; p<0.05
Table 2. MDA levels measured in tissue samples 
MDA
(nmol/g tissue)
C
x±SE
S
x±SE
T
x±SE
T+S
x±SE p
LIVER 34,82±1,60bc 36,71±1,24 ab 41,81±1,18 a 29,38±1,46 c 0,000
LUNG 19,95±0,94b 19,83±0,73b 24,27±0,69a 18,32±0,86b 0,000
KIDNEY 24,18±1,81b 27,32±1,39ab 32,83±1,33 a 27,82±1,65 ab 0,000
BRAIN 27,32±0,88a 22,72±0,68 b 28,35±0,65 a 17,09±0,79 c 0,000
TESTIS 20,28±2,05 b 19,58±1,58 b 29,54±1,51 a 17,97±1,87 b 0,000
MDA: Malondialdehyde; C: Control Group; T : Sub-chronic Thinner Inhalation Group; T+S: Sub-chronic Thinner 
Inhalation + Safranal Group; S: Safranal Group; X ± SE: mean ± standard error; a,b,c: different letters on the same line 
indicate a significant difference p<0.05
 Table 3. GSH levels measured in tissue samples 
GSH
(nmol/g tissue)
C
x±SE
S
x±SE
T
x±SE
T+S
x±SE p
LIVER 19,93±1,05 a 19,25±0,81ab 16,47±0,78 b 18,69±0,96ab 0,013
LUNG 16,46±0,70ab 16,71±0,54 a 17,37±0,52 a 13,64±0,64b 0,000
KIDNEY 15,99±0,98 ab 17,39±0,76a 12,91±0,72 c 14,09±0,89 bc 0,000
BRAIN 14,70±0,75 a 14,36±0,58 a 12,41±0,55b 13,14±0,69ab 0,015
TESTIS 18,8±1,6 a 18,71±1,22 ab 13,76±1,16 b 18,60±1,44ab 0,007
GSH: reduced glutathione; C: Control Group; T : Sub-chronic Thinner Inhalation Group; T+S: Sub-chronic Thinner 
Inhalation + Safranal Group; S: Safranal Group; X ± SE: mean ± standard error; a,b,c: different letters on the same line 
indicate a significant difference p<0.05
Table 4. TAS levels measured in tissue samples
TAS
(mmol Trolox Equiv./L)
C
x±SE
S
x±SE
T
x±SE
T+S
x±SE p
LIVER 0,89±0,07 a 0,39±0,05 b 0,38±0,05 b 0,80±0,06 a 0,000
LUNG 0,28±0,09 0,29±0,07 0,32±0,07 0,49±0,09 0,213
KIDNEY 0,56±0,07a 0,45±0,06 a 0,15±0,06 b 0,49±0,07 a 0,000
BRAIN 0,35±0,07 0,22±0,05 0,32±0,05 0,35±0,06 0,158
TESTIS 0,43±0,05 0,33±0,04 0,30±0,03 0,38±0,04 0,060
TAS: Total antioxidant status; C: Control Group; T : Sub-chronic Thinner Inhalation Group; T+S:Sub-chronic Thinner 
Inhalation + Safranal Group; S: Safranal Group; X ± SE: mean ± standard error; a,b,c: different letters on the same line 
indicate a significant difference p<0.05
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Table 5. TOS levels measured in tissue samples
TOS
(µmol H2O2Equiv./L)
C
x±SE
S
x±SE
T
x±SE
T+S
x±SE p
LIVER 18,24±2,03b 28,82±1,56 a 35,32±1,49 a 22,51±1,85 b 0,000
LUNG 13,24±1,89 16,17±1,46 16,75±1,39 13,26±1,73 0,129
KIDNEY 12,64±2,31 12,62±1,78 16,10±1,70 12,56±2,11 0,361
BRAIN 7,46±1,98 b 13,14±1,53 ab 17,26±1,46 a 15,44±1,81ab 0,001
TESTIS 11,74±1,25 11,74±0,97 13,77±0,92 10,91±1,14 0,193
TOS: Total oxidant status; C: Control Group; T : Sub-chronic Thinner Inhalation Group; T+S: Sub-chronic Thinner 
Inhalation + Safranal Group; S: Safranal Group; X ± SE: mean ± standard error; a,b,c: different letters on the same line 
indicate a significant difference p<0.05
Table 6. NO
x
 levels measured in tissue samples
NO
x
(μmol/g tissue)
C
x±SE
S
x±SE
T
x±SE
T+S
x±SE p
LIVER 7,23±1,314ab 12,09±1,02 a 9,32±0,97 a 3,00±1,19b 0,000
LUNG 4,32±0,89ab 6,86±0,69 a 6,54±0,66 a 2,85±0,82 b 0,000
KIDNEY 5,09±0,90 ab 8,63±0,69 a 6,99±0,67 a 2,29±0,82 b 0,000
BRAIN 3,32±1,01 b 7,71±0,78 a 6,98±0,74 a 3,62±0,92b 0,000
TESTIS 5,64±0,95 ab 5,87±0,73 a 6,69±0,69 a 2,81±0,86 b 0,006
NOx: Nitric oxide; C: Control Group; T : Sub-chronic Thinner Inhalation Group; T+S: Sub-chronic Thinner Inhalation 
+ Safranal Group; S: Safranal Group; X ± SE: mean ± standard error; a,b,c: different letters on the same line indicate a 
significant difference p<0.05
DISCUSSION
In the present study, it was observed that rats did 
not exhibit any escape reflexes during the applica-
tion in the first two weeks of the inhalation, however, 
rats became more aggressive and exhibited escaping 
movements after the third week, their urination and 
excretion increased, and the uncontrolled rotational 
movements and standing reflexes deteriorated. Such 
observations obtained during the present study sup-
ported the previous findings reported in the literature 
suggesting that thinner acted as a neurotoxic agent 
and there existed evidence of intoxication in the cen-
tral nervous system due to thinner inhalation (Bölük-
başı, 2005). It was also observed that the rats in the 
T+S group exhibited calmer behaviors contrary to the 
aggressive behaviors detected in the thinner inhala-
tion group. Such finding could be interpreted as the 
mitigating or suppressing effect of safranal in case of 
the intoxication due to thinner inhalation. However, 
such finding should be supported through research 
conducted at molecular level. The difference between 
the blood toluene levels of the rats in the T and T + 
S groups indicates that the groups inhaled the same 
level of thinner.
Hosseinzadeh et al. (2013) suggest that the oral ad-
ministration of safranal, in subacute toxicity test did 
not induce any toxic effects in many organs. Safranal 
at doses of 100 mg/kg by oral rout for 8 weeks did 
not cause any death in rats. However, an increase in 
the movement of animals was observed in the first 5 
minutes after the application. This might be related to 
the irritant nature of most essential oils.
Higher doses and longer durations of thinner inha-
lation increases the monooxygenases based on CYP-
450 and therefore results in ROS (Backes, 1993).. 
It is acknowledged that the toxic effects of organic 
solvents on cellular damage occurs due to the initi-
ation of lipid peroxidation by free oxygen radicals 
such as superoxide anion ferryl and hydroxyl ions or 
more generally by the ROS (Mattia et al., 1991, 1993; 
Ahmed-Choudhury et al.,1998). Konuk et al. (2012) 
reported that sub-chronic thinner inhalation in rats 
increased free radical production. Additionally, expo-
sure to sub-chronic toluene was reported not only to 
increase ROS production measures, but also to sig-
nificantly affect various antioxidants (Kodavanti et al. 
2015). 
Given that the membrane phospholipids are the 
main target of free radicals, concentrations of MDA, 
one of the end products of lipid peroxidation (LP), 
were reported to be directly related to the severity of 
damage (Aleksandrovskii et al., 1988). In the pres-
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ent study, once the MDA levels of the thinner group 
were compared with the MDA levels of the control 
group, it was observed that the MDA levels signifi-
cantly increased in liver, lung, testis and kidney tis-
sues, however, no significant increase was detected 
for the brain tissues despite the relative increase. Such 
findings were found to be consistent with the previ-
ous studies (Ulakoglu et al., 1998a, 1998b; Karaözler 
et al., 2002; Halifeoğlu et al., 2000). It was reported 
that in vivo and in vitro exposure to thinner or tolu-
ene accelerated the ROS formation in the brain, liver, 
kidney and lungs of rats and increased lipid (Mattia 
et al., 1991;1993; Halifeoğlu et al., 2000; Baydas et 
al., 2005). In parallel with these results, it is possible 
to state that sub-chronic thinner inhalation increased 
lipid peroxidation in tissues in the present study. It 
was reported that saffron and its components exhib-
ited hydroxyl and DPPH radical scavenging activi-
ty (Hosseinzadeh et al., 2009; Assimopoulou et al., 
2013). The literature review yielded no studies that 
focused on investigating the effects of safranal on 
thinner toxicity. In studies conducted through the use 
of safranal as an antioxidant molecule, it was stated 
that the increased MDA levels were decreased due to 
the antioxidative properties of safranal (Hosseinzadeh 
and Sadeghnia 2005; Mehdizadeh et al., 2013; Sade-
ghnia et al., 2013; Samarghandian et al., 2014, 2015).
In the present study, the tissue MDA levels in T+S 
groups were found to be close to the levels of the con-
trol group and such finding indicated that safranal had 
a protective effect against the damaging effects of ox-
idation reactions in the organs and had an antioxidant 
potential in preventing lipid peroxidation, however 
such potentials did not exhibit uniform intensities for 
all tissue types. 
GSH protects cells from oxidative damage through 
a direct interaction with the free radicals of the sulf-
hydryl group or through acting as a cofactor (Valko 
et al., 2006). In the present study, once the GSH lev-
els of the tissue samples of the five organs of the T 
group were compared to those of the control group, it 
was determined that the GSH levels in the liver, testis, 
brain and kidney tissues were statistically significant-
ly lower. On the other hand, there existed a statistical-
ly insignificant increase in the lung tissues, contrary 
to the findings in literature. Similar studies that fo-
cused on the effects of thinner on GSH levels reported 
that GSH levels decreased due to thinner inhalation 
(Baydas et al., 2003,2005; Ulakoğlu et al.,1998a; El-
Nabı Kamel and Shehata 2008; Dillioglugil et al., 
2005; Ahmadizadeh et al., 2014). In conclusion, the 
decreasing GSH levels in all tissues except the lung 
were considered to be due to the free oxygen radi-
cals such as superoxide anions, ferryl and hydroxyl 
ions formed by the catabolism of thinner metabolites 
such as benzyl alcohol and benzaldehyde, which in-
creased due to thinner inhalation. Hazman and Boz-
kurt (2015) and Samarghandian et al. (2014) reported 
that safranal increased the GSH levels in diabetic rats 
and suppressed the oxidative stress based on diabetes. 
In the present study, it was observed that the GSH lev-
els decreased in the liver, testis, brain and kidney tis-
sues of the T group were back to the control levels in 
the T+S group. Therefore, the authors considered that 
the excessive amounts of free radicals due to thinner 
inhalation were neutralized by safranal and the oxida-
tive stress levels were decreased or safranal increased 
the biosynthesis GSH.
It was reported that the antioxidant/oxidant sta-
tus in the body was more simply evaluated by TAS 
and TOS measurements and gave an insight about 
the sensitive balance between the in vivo oxidants 
and antioxidants as a result of synergistic interactions 
(Ghiselli et al., 2000; Erel, 2004; Erel, 2005; Kayar et 
al., 2015). However, once the antioxidant/oxidant bal-
ance was deteriorated in favor of oxidants and oxida-
tive stress occurred, a significant negative correlation 
could be observed between the TAS and TOS levels 
(Erel, 2005). Considering the TAS and TOS levels 
for all tissues, TAS levels were determined to nu-
merically increase in the T+S group when compared 
to the T group, and the TOS levels were determined 
to decrease. Once the data from the Safranal group 
were compared to the data of the control group, the 
expected TAS-TOS negative correlation could not be 
observed. On the other hand, similar studies that fo-
cused on the effects of thinner on TAS and TOS levels 
indicated that the decrease in total antioxidant capac-
ity levels due to thinner inhalation was a result of the 
oxidative stress (Bayil et al., 2008; Konuk et al.,2012 
Hazman and Bozkurt (2015) suggested that safran-
al increased the TAS levels and decreased the TOS 
levels especially in diabetic rats, hence, acted exactly 
similar to an antioxidant. The present study also states 
that safranal has a protective effect against the oxida-
tive damage due to thinner inhalation. 
NO is a free radical that is defined as a biolog-
ical signal molecule and plays an important role in 
both physiological and pathophysiological processes 
(Velayutham. and Zweier, 2013). In the presence of 
stressors, it could be produced by the catalytic ac-
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tion of inducible NO-synthase (iNOS) and could be 
at higher concentrations. NO could lead to damage 
to proteins, lipids and the DNA through direct or su-
peroxide reaction and thus lead to the formation of a 
highly reactive peroxide anion (Rahal et al., 2014). 
In the present study, the increased NO
x 
levels in the 
T groups in comparison to the control group indicat-
ed the presence of thinner metabolites and their acti-
vated release. While Konuk et al. (2012) determined 
that nitric oxide metabolites in rats were higher in T 
groups when compared to the control, Maniscalco et 
al. (2004) concluded that NO
x
 levels increased in the 
blood of shoe and leather workers, breathing organic 
solvents such as toluene, xylene and methyl-ethyl ke-
tone. Once the NO
x
 levels of the S group were com-
pared to those of the control group, a numeric increase 
was observed for all tissues. Farahmand et al. (2013) 
stated that safranal could be effective as a hormetin 
and in cases of mild oxidative damage that causes 
the activation of the antioxidative enzymes. Several 
studies that investigated the anti-inflammatory and 
antioxidant potentials of safranal reported a decrease 
in NO
x
 level due to safranal administration (Samar-
ghandian et al., 2014; Bukhari et al., 2015; Hazman 
and Bozkurt 2015). In the present study, decreased 
NO
x
 levels in the T+S group indicated that safranal 
decreased the thinner-based stressors. 
CONCLUSIONS
In conclusion, it was determined that the oxidative 
stress in liver, lung, brain, testis and kidney tissues 
developed due to thinner inhalation was eliminated or 
mitigated due to safranal administration, either by de-
creasing the NO
x
, MDA and TOS levels or by increas-
ing the GSH and TAS levels. Safranal was considered 
to have important antioxidant potentials in protecting 
the studied tissues against the harmful effects of ox-
idative stress. However, it was evident that safranal 
did not provide a uniform effect for every tissue. Al-
though safranal appears to be a biological antioxidant, 
there exists scarce evidence of its effect as a direct 
chemical antioxidant. However, in the present study, 
the comparison between the data of the safranal group 
and the control group indicated close values for NO
x
 
and TOS levels of the T group and the expected TAS-
TOS correlation was not achieved. Such results could 
indicate the significance of safranal dose in medical 
applications. Therefore, it was considered that safran-
al, effective as a hormetin, could also act indirectly as 
an antioxidant. Within the scope of these outcomes, 
it becomes essential to consider not to exceed the 
specific limit values of solvent inhalation in sever-
al industries. It is as well considered significant that 
applying treatment methods that include safranal for 
the rehabilitation of volatile substance addicts could 
contribute to the development of new treatment mod-
ulations.
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